Monitor for upcoming data readouts from the Phase 2b ASPIRE trial of buloxibutid in IPF, which is the primary catalyst for the stock. This CSO appointment alone is not a trading event.
Price Chart
Executive Summary
Vicore Pharma announced the appointment of Rob Slack, PhD, FRSB, as Chief Scientific Officer, effective July 6, 2026. Dr. Slack joins from GSK where he served as VP and Head of Respiratory Biology, bringing over 20 years of fibrosis and respiratory translational science experience. This is a routine executive change with no material financial information disclosed.
Key Facts
- Rob Slack appointed Chief Scientific Officer, effective July 6, 2026
- Dr. Slack previously served as VP and Head of Respiratory Biology at GSK and acting CSO at Galecto
- Outgoing CSO Johan Raud transitions to Senior Advisor role
- No financial terms, compensation details, or changes to corporate strategy disclosed
Financial Impact
No financial figures disclosed in the filing
Risk Factors
- No drug candidate has been approved by the FDA; buloxibutid remains in clinical development
- Key upcoming milestone is the ASPIRE Phase 2b trial, which carries binary outcome risk
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-080617 |
| Document: tm2619347d1_ex99-1.htm | 0001104659-26-080617 |
| Document: 0001104659-26-080617-index-headers.html | 0001104659-26-080617 |
| Document: 0001104659-26-080617-index.html | 0001104659-26-080617 |
| Document: 0001104659-26-080617.txt | 0001104659-26-080617 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 6-K | $10.51 | awaiting T+20 | — | $9.40 (−10.56%) |
Oct 13, 2026 13d ago | SC 13G | $9.08 | awaiting T+20 | — | $9.40 (+3.52%) |
Sep 30, 2026 25d ago | 6-K | $9.43 | awaiting T+20 | — | $9.40 (−0.32%) |
Jul 6, 2026 16w ago | 6-K | $16.25 $11.40 | ▼ −29.85% | ▼ −29.28% | $9.40 (−42.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers